{"id":"cxa-201-and-metronidazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Metallic taste (metronidazole)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CXA-201 is a rifamycin-class antibiotic designed for local activity without systemic absorption. When combined with metronidazole, a nitroimidazole antibiotic effective against anaerobic bacteria and protozoa, the two agents provide broad-spectrum coverage against polymicrobial infections. This combination targets complementary bacterial populations to enhance therapeutic efficacy.","oneSentence":"CXA-201 is a non-absorbed topical antibiotic that works synergistically with metronidazole to treat bacterial infections, particularly in the gastrointestinal tract or as a topical agent.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:08:14.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clostridioides difficile infection (CDI)"},{"name":"Polymicrobial intra-abdominal infections"}]},"trialDetails":[{"nctId":"NCT01445678","phase":"PHASE3","title":"Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2011-12-23","conditions":"Complicated Intra-abdominal Infection","enrollment":494}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CXA-201 and metronidazole","genericName":"CXA-201 and metronidazole","companyName":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","companyId":"cubist-pharmaceuticals-llc-a-subsidiary-of-merck-co-inc-rahway-new-jersey-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CXA-201 is a non-absorbed topical antibiotic that works synergistically with metronidazole to treat bacterial infections, particularly in the gastrointestinal tract or as a topical agent. Used for Clostridioides difficile infection (CDI), Polymicrobial intra-abdominal infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}